Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Retrieved on:
Tuesday, February 7, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Orange, Neoplasm, Bristol Myers Squibb, Calendar, ADC, District court, News, 1836 U.S. Patent Office fire, Clinical trial, Absorption, United States District Court for the Eastern District of Texas, Partnership, Orange Book, Relatlimab, IMDC, Toxicity, Patent, Checkmate, Trial of the century, Acceleration, Breast, Potential, RECIST, Catalent, Software, Tumor microenvironment, SIRP, Antibody, FDA, Progression-free survival, DC, MSN, Douglas v. U.S. District Court ex rel Talk America, Society, Ipilimumab, T helper cell, PDC, RCC, ASCO, OS, CDK7, BMS, Webcast, Investigational New Drug, Royalty payment, ANDA, Initial, ENA, Allele, Cabozantinib, Blinded, LAG-3, Conjugation, Conference, IND, Online shopping, Pharmaceutical industry, Communications satellite, Nivolumab, Exelixis, Patient, Exatecan
In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.
Key Points:
- In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.
- Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2022, Exelixis earned $33.9 million and $121.4 million, respectively, in royalty revenues.
- Exelixis expects its partner Sairopa to file an Investigational New Drug application (IND) for ADU-1805 in the first quarter of 2023.
- Exelixis management will discuss the company’s financial results for the fourth quarter and full year of 2022 and provide a general business update during a conference call beginning at 5:00 p.m.